Effects of antidepressants on quality of life in women with premenstrual dysphoric disorder

PharmacoEconomics

Volumn 23, Issue 5, 2005, Pages 433-444

  Freeman, Ellen W ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Department of Obstetrics/Gynecology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BUSPIRONE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; FLUOXETINE; FLUVOXAMINE; LEUPRORELIN; MAPROTILINE; NEFAZODONE; NORADRENALIN; PAROXETINE; SEROTONIN; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SPIRONOLACTONE; VENLAFAXINE;

CLINICAL TRIAL; DIARRHEA; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; ECONOMIC ASPECT; FATIGUE; FUNCTIONAL DISEASE; HEADACHE; HEALTH CARE; HEALTH CARE COST; HUMAN; INSOMNIA; LETHARGY; LIBIDO DISORDER; MENSTRUAL CYCLE; NAUSEA; NONHUMAN; ORGASM DISORDER; PREMENSTRUAL DYSPHORIC DISORDER; PRIORITY JOURNAL; QUALITY OF LIFE; RELIABILITY; REVIEW; SOCIAL ASPECT; SUSTAINED RELEASE FORMULATION;

ADULT; ANTIDEPRESSIVE AGENTS; FEMALE; HUMANS; PREMENSTRUAL SYNDROME; QUALITY OF LIFE;

EID: 22244472670     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200523050-00003     Document Type: Review

References (97)

1. ACOG Practice Bulletin. Premenstrual syndrome. Int J Gynecol Obstet 2001 May; 73 (2): 183-90
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994: 350
3. Freeman EW, Rickels K, Schweizer E, et al. Relationships between age and symptom severity among women seeking medical treatment for premenstrual symptoms. Psychol Med 1995 Mar; 25 (2): 309-15
4. Wittchen HU, Becker E, Leib R, et al. Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med 2002 Jan; 32 (1): 119-32
5. Freeman EW, Rickels K, Sondheimer SJ. Premenstrual symptoms and dysmenorrhea in relation to emotional distress factors in adolescents. J Psychosom Obstet Gynecol 1993; 14 (1): 41-50
6. Sternfeld B, Swindle R, Chawla A, et al. Severity of premenstrual symptoms in a health maintenance organization population. Obstet Gynecol 2002; 99: 1014-24
7. Roca CA, Schmidt PJ, Rubinow DR. A follow-up study of premenstrual syndrome. J Clin Psychiatry 1999; 60: 763-6
8. Yonkers KA, Barnett LK, Carmody T, et al. Serial discontinuation of SSRI treatment for PMDD [abstract]. Biol Psych 1998; 43 Suppl. 8: 358
9. de la Gandara Martin JJ. Premenstrual dysphoric disorder: long-term treatment with fluoxetine and discontinuation. Actas Luso Esp Neurol Psiquiatr Cienc Afines 1997; 25: 235-42
10. Freeman EW, Sondheimer SJ, Rickels K, et al. A pilot naturalistic follow-up of extended sertraline treatment for severe premenstrual syndrome. J Clin Psychopharm 2004; 24 (3): 351-3
11. Angst J, Sellara R, Stolar M, et al. The epidemiology of peri-menstrual psychological symptoms. Acta Psychiatr Scand 2001; 104: 110-6
12. Cohen LS, Soares CN, Otto MW, et al. Prevalence and predictors of premenstrual dysphoric disorder (PMDD) in older premenopausal women: the Harvard study of moods and cycles. J Affect Disord 2002; 70 (2): 125-32
13. Steiner M, Macdougall M, Brown E. The premenstrual symptoms screening tool (PSST) for clinicians. Arch Women Ment Health 2003; 6: 203-9
14. Steiner M, Born L. Advances in the diagnosis and treatment of premenstrual dysphoria. CNS Drugs 2000 Apr; 13 (4): 287-304
15. Banerjee N, Roy KK, Takkar D. Premenstrual dysphoric disorder: a study from India. Int J Fertil Womens Med 2000 Sep-Oct; 45 (5): 342-4
16. Khella AK. Epidemiologic study of premenstrual symptoms. J Egypt Public Health Assoc 1992; 67 (1-2): 109-18
17. McMaster J, Cormie K, Pitts M. Menstrual and premenstrual experiences of women in a developing country. Health Care Women Int 1997 Nov-Dec; 18 (6): 533-41
18. Montero P, Bernis C, Loukid M, et al. Characteristics of menstrual cycles in Moroccan girls: prevalence of dysfunctions and associated behaviours. Ann Hum Biol 1999 May-Jun; 26 (3): 243-9
19. van den Akker OB, Eves FF, Service S, et al. Menstrual cycle symptom reporting in three British ethnic groups. Soc Sci Med 1995 May; 40 (10): 1417-23
20. Chandra PS, Chaturvedi SK. Cultural variations of premenstrual experience. Int J Soc Psychiatry 1989 winter; 35 (4): 343-9
21. Chang AM, Holroyd E, Chau JP. Premenstrual syndrome in employed Chinese women in Hong Kong. Health Care Women Int 1995 Nov-Dec; 16 (6): 551-61
22. Merikangas KR, Foeldenyi M, Angst J. The Zurich Study. XIX. Patterns of menstrual disturbances in the community: results of the Zurich Cohort Study. Eur Arch Psychiatry Clin Neurosci 1993; 243 (1): 23-32
23. Pearlstein TB, Halbreich U, Batzar ED, et al. Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo. J Clin Psychiatry 2000; 61: 101-9
24. Chawla A, Swindle R, Long S. Premenstrual dysphoric disorder: is there an economic burden of illness? Med Care 2002; 40(11): 1101-12
25. Morgan M, Rapkin AJ, D'Elia L, et al. Cognitive functioning in premenstrual syndrome. Obstet Gynecol 1996; 88: 961-6
26. Resnick A, Perry W, Parry B, et al. Neuropsychological performance across the menstrual cycle in women with and without premenstrual dysphoric disorder. Psychiatry Res 1998; 77: 147-58
27. Robinson RL, Swindle RW. Premenstrual symptom severity: impact on social functioning and treatment-seeking behaviors. J Womens Health 2000; 9 (7): 757-68
28. Campbell EM, Peterkin D, O'Grady K, et al. Premenstrual symptoms in general practice patients: prevalence and treatment. J Reprod Med 1997; 42: 637-46
29. Kuczmierczyk AR, Labrum AH, Johnson CC. Perception of family and work environments in women with premenstrual syndrome. J Psychosom Res 1992; 36: 787-95
30. Borenstein JE, Dean BB, Endicott J, et al. Health and economic impact of the premenstrual syndrome. J Reprod Med 2003; 48: 515-24
31. Hallman J, Georgiev N. The premenstrual syndrome and absence from work due to illness. J Psychosom Obstet Gynaecol 1987; 6: 111-9
32. Halbreich U, Borenstein J, Pearlstein T, et al. The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology 2003; 28: 1-23
33. Murray CJL, Lopez AD. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Global burden of disease and injury series. Boston: The Harvard School of Public Health, on behalf of the World Health Organization and the World Bank, 1996
34. Hall RCW, Wise MG. The clinical and financial burden of mood disorders: cost and outcome. Psychosomatics 1995; 36 (2): S11-8
35. Simon GE, Vonkorff M, Barlow W. Health-care costs of primary-care patients with recognized depression. Arch Gen Psychiatry 1995; 52 (10): 850-6
36. Johnson J, Weissman MM, Klerman GL. Service utilization and social morbidity associated with depressive symptoms in the community. JAMA 1992; 267: 1478-83
37. Horwath E, Johnson J, Klerman GL, et al. Depressive symptoms as relative and attributable risk factors for first-onset major depression. Arch Gen Psychiatry 1992; 49: 817-23
38. Barnard K, Frayne SM, Skinner KM, et al. Health status among women with menstrual symptoms. J Womens Health 2003; 12 (9): 911-9
39. Rosen LN, Moghadam LZ, Endicott J. Relationship between premenstrual symptoms and general well-being. Psychosomatics 1990 Winter; 31 (1): 47-54
40. Hartlage SA, Arduino KE, Gehlert S. Premenstrual dysphoric disorder and risk for major depressive disorder: a preliminary study. J Clin Psychol 2001; 57 (12): 1571-8
41. Rubinow DR, Schmidt PJ, Roca CA. Estrogen-serotonin interactions: implications for affective regulation. Biol Psychiatry 1998; 44: 839-50
42. Dimmock PW, Wyatt KM, Jones PW, et al. Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review. Lancet 2000; 256: 1131-6
43. Wyatt KM, Dimmock PW, O'Brien PM. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev 2002; (4): CD001396
44. Steiner M, Steinberg S, Stewart D, et al. Fluoxetine in the treatment of premenstrual dysphoria. N Engl J Med 1995; 332: 1529-34
45. Wood SH, Mortola JF, Chan YF, et al. Treatment of premen-strual syndrome with fluoxetine: a double-blind, placebo-con-trolled, crossover study. Obstet Gynecol 1992; 80: 339-44
46. Menkes DB, Taghavi E, Mason PA. Fluoxetine treatment of severe premenstrual syndrome. BMJ 1992; 305: 346-7
47. Ozeren S, Corakci A, Yucesoy I, et al. Fluoxetine in the treatment of premenstrual syndrome. Eur J Obstet Gynecol Reprod Biol 1997; 73: 167-70
48. Pearlstein TB, Stone AB, Lund SA. Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder. J Clin Psychopharmacol 1997; 17: 261-6
49. Su TP, Schmidt PJ, Danaceau MA, et al. Fluoxetine in the treatment of premenstrual dysphoria. Neuropsychopharmacology 1997; 16: 346-56
50. Cohen LS, Miner C, Brown E, et al. Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerized diaries. Obstet Gynecol 2002; 100: 435-44
51. Halbreich U, Bergeron R, Yonkers KA, et al. Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstet Gynecol 2002 Dec; 100 (6): 1219-29
52. Freeman EW, Rickels K, Sondheimer SJ, et al. Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder. Arch Gen Psychiatry 1999; 56: 932-9
53. Yonkers KA, Halbreich U, Freeman E, et al. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment: a randomized controlled trial. JAMA 1997; 278: 983-8
54. Young SA, Hurt PH, Benedek DM, et al. Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase: a randomized, double-blind, placebo-controlled cross over trial. J Clin Psychiatry 1998; 59: 76-80
55. Jermain DM, Preece CK, Sykes RL, et al. Luteal phase sertraline treatment for premenstrual dysphoric disorder: results of a double-blind, placebo-controlled, crossover study. Arch Fam Med 1999; 8: 328-32
56. Halbreich U, Smoller JW. Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome. J Clin Psychiatry 1997; 58: 399-402
57. Eriksson E, Hedberg A, Andersch B, et al. The SRI paroxetine is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome: a placebo-controlled trial. Neuropsychopharmacology 1995; 12: 167-76
58. Wikander I, Sundblad C, Andersch B, et al. Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle? J Clin Psychopharmacol 1998; 18: 390-9
59. Freeman EW, Rickels K, Yonkers KA, et al. Venlafaxine in the treatment of premenstrual dysphoric disorder. Obstet Gynecol 2001; 98: 737-44
60. Sundblad C, Modigh K, Andersch B, et al. Clomipramine effectively reduces premenstrual irritability and dysphoria: a placebo-controlled trial. Acta Psychiatr Scand 1992; 85: 39-47
61. Sundblad C, Hedberg M, Eriksson E. Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo controlled trial. Neuropsychopharmacology 1993; 9: 133-45
62. Freeman EW, Rickels K, Sondheimer SJ, et al. Nefazodone in the treatment of premenstrual syndrome: a preliminary study. J Clin Psychopharmacol 1994; 14: 180-6
63. Freeman EW, Rickels K, Sondheimer SJ. Fluvoxamine for premenstrual dysphoric disorder: a pilot study. J Clin Psychiatry 1996; 57 Suppl. 8: 56-9
64. Graham CA, Sherwin BB. A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive. J Psychosom Res 1992 Apr; 36 (3): 257-66
65. Freeman EW, Kroll R, Rapkin A, et al. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Womens Health Gend Based Med 2001 Jul-Aug; 10 (6): 561-9
66. Brown CS, Ling FW, Andersen RN, et al. Efficacy of depot leuprolide in premenstrual syndrome: effect of symptom severity and type in a controlled trial. Obstet Gynecol 1994 Nov; 84 (5): 779-86
67. Freeman EW, Sondheimer SJ, Rickels K. Gonadotropin-releasing hormone agonist in the treatment of premenstrual symptoms with and without ongoing dysphoria: a controlled study. Psychopharmacol Bull 1997; 33 (2): 303-9
68. Hammarback S, Backstrom T. Induced anovulation as treatment of premenstrual tension syndrome: a double-blind cross-over study with GnRH-agonist versus placebo. Acta Obstet Gynecol Scand 1988; 67 (2): 159-66
69. Hussain SY, Massil JH, Matta WH, et al. Buserelin in premenstrual syndrome. Gynecol Endocrinol 1992 Mar; 6 (1): 57-64
70. Wyatt K, Dimmock P, Jones P, et al. Efficacy of progesterone and progestogens in management of premenstrual syndrome: systematic review. BMJ 2001 Oct 6; 323 (7316): 776-80
71. Berger CP, Presser B. Alprazolam in the treatment of two subsamples of patients with late luteal phase dysphoric disorder: a double-blind, placebo-controlled crossover study. Obstet Gynecol 1994 Sep; 84 (3): 379-85
72. Freeman EW, Rickels K, Sondheimer SJ, et al. A double-blind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome. JAMA 1995 Jul 5; 274 (1): 51-7
73. Harrison WM, Endicott J, Nee J. Treatment of premenstrual dysphoria with alprazolam: a controlled study. Arch Gen Psychiatry 1990 Mar; 47 (3): 270-5
74. Rickels K, Freeman E, Sondheimer S. Buspirone in treatment of premenstrual syndrome [letter]. Lancet 1989 Apr 8; 1 (8641): 777
75. Smith S, Rinehart JS, Ruddock VE, et al. Treatment of premenstrual syndrome with alprazolam: results of a double-blind, placebo-controlled, randomized crossover clinical trial. Obstet Gynecol 1987 Jul; 70 (1): 37-43
76. Dennerstein L, Morse C, Burrows G, et al. Alprazolam in the treatment of premenstrual syndrome. In: Dennerstein L, Fraser I, editors. Hormones and behavior. New York (NY): Elsevier Science Publishing, 1986: 175-82
77. Schmidt PJ, Grover GN, Rubinow DR. Alprazolam in the treatment of premenstrual syndrome: a double-blind, placebo-controlled trial. Arch Gen Psychiatry 1993 Jun; 50 (6): 467-73
78. Thys-Jacobs S, Starkey P, Bernstein D, et al. Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Premenstrual Syndrome Study Group. Am J Obstet Gynecol 1998 Aug; 179 (2): 444-52
79. Pearlstein T, Steiner M. Non-antidepressant treatment of pre-menstrual syndrome. J Clin Psychiatry 2000; 61 Suppl. 12: 22-7
80. Stevinson C, Ernst E. Complementary/alternative therapies for premenstrual syndrome: a systematic review of randomized controlled trials. Am J Obstet Gynecol 2001 Jul; 185 (1): 227-35
81. Pearlstein T. Selective serotonin reuptake inhibitors for premenstrual dysphoric disorder. Drugs 2002; 62 (13): 1869-85
82. Altshuler LL, Cohen LS, Moline ML, et al. The Expert Consensus Guideline Series: treatment of depression in women. Postgrad Med 2001 Mar; (Spec No): 1-107
83. Freeman EW, Sondheimer SJ, Polansky M, et al. Predictors of response to sertraline treatment of severe premenstrual syndromes. J Clin Psychiatry 2000; 61: 579-84
84. Sundström-Poromaa I, Bixo M, Björn I, et al. Compliance to antidepressant drug therapy for treatment of premenstrual syndrome. J Psychosom Obstet Gynecol 2000; 21: 205-11
85. Miner C, Brown E, McCray S, et al. Weekly luteal-phase dosing with enteric-coated fluoxetine 90mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial. Clin Ther 2002; 24: 417-33
86. Zajecka J, Tracey KA, Mitchell S. Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review. J Clin Psychiatry 1997; 58 (7): 291-7
87. Pearlstein T, Gillespie JA. When should premenstrual dosing in PMDD end? [poster]. 155th Annual APA Meeting; 2002 May 18-23, Philadelphia
88. Clayton AH, Pradko JF, Croft HA, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 2002; 63: 357-66
89. Steiner M, Brown E, Trzepacz P, et al. Fluoxetine improves functional work capacity in women with premenstrual dysphoric disorder. Arch Women Ment Health 2003; 6: 71-7
90. Weissman MM, Bothwell S. Assessment of social adjustment by patient self-report. Arch Gen Psychiatry 1976; 33: 1111-5
91. Endicott J, Nee J, Harrison W, et al. Quality of life enjoyment and satisfaction questionnaire: a new measure. Psychopharmacol Bull 1993; 29: 321-6
92. Endicott J, Harrison W. Daily rating of severity of problems form. New York (NY): Department of Research Assessment and Training, New York State Psychiatric Institute, 1990
93. Steiner M, Haskett RF, Carroll BJ. Premenstrual tension syndrome: the development of research diagnostic criteria and new rating scales. Acta Psychiatr Scand 1980; 62: 177-90
94. Leon AC, Olfson M, Portera L, et al. Assessing psychiatric impairment in primary care with the Sheehan Disability Scale. Int J Psychiatry Med 1997; 27: 93-105
95. McGahuey CA, Gelenberg AJ, Laukes CA, et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther 2000; 26 (1): 25-40
96. Yonkers K, Gillespie JA. Quality of life impairment and response in PMDD [poster]. 155th Annual APA Meeting; 2002 May 18-23, Philadelphia
97. Kraemer GR, Kraemer RR. Premenstrual syndrome: diagnosis and treatment experiences. J Womens Health 1998; 7: 893-907